Prevalence of frailty and its association with cognition in preclinical Alzheimer's disease: a cross-sectional analysis of baseline data from the A4 study.
Background The prevalence and role of frailty in preclinical Alzheimer's disease (AD) is unclear. Methods Cross-sectional analyses of pre-randomization data from the Anti-Amyloid Treatment in Asymptomatic AD (A4) study were analysed to derive two models of a frailty index (FI)—full [FI-Full] and cog...
| Publicado en: | Age & Ageing Vol. 55; no. 1; pp. 1 - 11 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | Artículo |
| Publicado: |
Oxford University Press / USA
Jan2026
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ssf&AN=192513119&site=ehost-live header: @attributes: shortDbName: ssf uiTerm: 192513119 longDbName: Social Sciences Full Text (H.W. Wilson) uiTag: AN controlInfo: bkinfo: jinfo: jid: 00020729 AGA jtl: Age & Ageing issn: 00020729 maglogo: N pubinfo: dt: Jan2026 vid: 55 iid: 1 pid: 622 pub: Oxford University Press / USA artinfo: ui: 192513119 10.1093/ageing/afaf378 ppf: 1 ppct: 10 formats: tig: atl: Prevalence of frailty and its association with cognition in preclinical Alzheimer's disease: a cross-sectional analysis of baseline data from the A4 study. aug: au: Huynh, Andrew L H Wang, Shunran Lee, Kathryn Amadoru, Sanka Wrigley, Scott Zisis, Georgios Ernstrom, Karin Raman, Rema Aisen, Paul Sperling, Reisa A affil: Department of Geriatric Medicine, Austin Health, Heidelberg, Melbourne, Victoria, AustraliaDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Melbourne, Victoria, AustraliaThe Florey Institute of Neuroscience and Mental Health, Parkville, Melbourne, Victoria, Australia Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, USA Department of Geriatric Medicine, Austin Health, Heidelberg, Melbourne, Victoria, Australia Department of Geriatric Medicine, Austin Health, Heidelberg, Melbourne, Victoria, AustraliaDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Melbourne, Victoria, Australia The Florey Institute of Neuroscience and Mental Health, Parkville, Melbourne, Victoria, Australia Department of Neurology, Massachusetts General Hospital, Boston, MA, USACenter for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USAHarvard Medical School, Boston, MA, USA su: Australia Cross-sectional method Old age Alzheimer's disease diagnosis Pearson correlation (Statistics) Cognitive testing Research funding T-test (Statistics) Frail elderly Brain Logistic regression analysis Positron emission tomography Chi-squared test Multivariate analysis Descriptive statistics Odds ratio Amyloid Neuropsychological tests Cognition disorders Early diagnosis Data analysis software Confidence intervals Biomarkers Amyloid beta-protein precursor sug: subj: Cross-sectional method Old age Australia Diagnostic Imaging Centers Alzheimer's disease diagnosis Pearson correlation (Statistics) Cognitive testing Research funding T-test (Statistics) Frail elderly Brain Logistic regression analysis Positron emission tomography Chi-squared test Multivariate analysis Descriptive statistics Odds ratio Amyloid Neuropsychological tests Cognition disorders Early diagnosis Data analysis software Confidence intervals Biomarkers Amyloid beta-protein precursor keyword: alzheimer's disease amyloid cognition cognitive decline cognitive impairment copyrightHolder:British Geriatrics Society copyrightYear:2026 frailty https://dx.doi.org/10.1093/ageing/afaf378 inLanguage:en older adults publisher:Oxford University Press sameAs:https://pubmed.ncbi.nlm.nih.gov/41569280/ alzheimer's disease amyloid cognition cognitive decline cognitive impairment copyrightHolder:British Geriatrics Society copyrightYear:2026 frailty https://dx.doi.org/10.1093/ageing/afaf378 inLanguage:en older adults publisher:Oxford University Press sameAs:https://pubmed.ncbi.nlm.nih.gov/41569280/ ab: Background The prevalence and role of frailty in preclinical Alzheimer's disease (AD) is unclear. Methods Cross-sectional analyses of pre-randomization data from the Anti-Amyloid Treatment in Asymptomatic AD (A4) study were analysed to derive two models of a frailty index (FI)—full [FI-Full] and cognitive variables removed [FI-CVR]. The prevalence of frailty (FI > 0.25) according to amyloid status (Aβ+/−), and the association of frailty and cognition (determined by the Preclinical Alzheimer Cognitive Composite (PACC) score) and whether frailty moderates the relationship between amyloid status and cognition was assessed, adjusting for age, sex and education. Results Four thousand four hundred eighty-six participants were included (mean age 71.3 ± 4.7 years, 30% participants Aβ+, 59% female). The prevalence of frailty in preclinical AD was 22% (or 44% when cognitive variables were removed from the FI). Using either FI model, in adjusted analyses, Aβ+ participants were more likely to be frail compared to Aβ− [FI-Full—Odds ratio (OR) 1.43 95% confidence interval (CI) 1.20–1.71, P < .001; FI-CVR—OR 1.21 95% CI 1.05–1.40, P < .008]. Frail participants had lower PACC scores compared to non-frail participants, on average (FI-Full—PACC score −0.58 95% CI −0.76 to −0.40, P < .001; FI-CVR—PACC score −0.26 95% CI −0.40 to −0.12, P < .001). Frailty did not influence the relationship between Aβ status and cognition. Conclusions In a cohort screened for a preclinical AD trial, elevated Aβ levels were associated with frailty and frailty was associated with reduced cognitive performance independent of elevated Aβ levels. These associations, and whether or not frailty is associated with longitudinal cognitive decline independent of Aβ status, warrant further study. pubtype: Academic Journal doctype: Article src: R language: English refInfo: copyright: @attributes: flag: N holdings: @attributes: islocal: N |
|---|